Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
Headache The Journal of Head and Face Pain2025Vol. 65(6), pp. 919–932
Citations Over TimeTop 10% of 2025 papers
David W. Dodick, Stewart J. Tepper, Jessica Ailani, Ani C. Khodavirdi, Nico Pannacciulli, Alan Fu, Shia T. Kent, Karminder Gill, Robert Urman, Sam S. Oh
Abstract
In this analysis of the MarketScan medical claims database, we found no difference in the risk of vascular events in patients treated with erenumab versus other anti-CGRP pathway mAbs or onabotulinumtoxinA.
Related Papers
- → The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine(2002)85 cited
- → The role of concomitant headache types and non‐headache co‐morbidities in the underdiagnosis of migraine.(2003)16 cited
- → TOTAL 5-HYDROXYINDOLES IN BLOOD RELATED to MIGRAINE ATTACKS(1976)14 cited
- → Migraine, Migraine Variants, and Related Headaches(1989)5 cited
- [Migraine and the influence of hormones].(2008)